Gilead Sciences

US · GILD #83 by market cap Listed 1992 AI Rating C 63

151.00 -0.23 -0.15%

Collector offline (last heartbeat: 15950s ago) · 2026-09-04 20:02

Pre-market 149.28 -1.28%

After-hours 151.00 0.00%

Overnight 150.73 -0.32%

Mkt cap: 187.23B
P/E (TTM): -56.98
P/B: 15.83
EPS: 6.78
Div yield: 2.13%
52W pos: 91%

Revenue annual, last 8 years

Latest year +2.40% YoY

Margins

Gross margin: 78.83%
Operating margin: 39.74%
Net margin: 28.90%

Key ratios & quality

Enterprise value: 202.55B
Altman Z-Score: 4.70

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

✦ AI Financial Health how this is computed

Good

Altman Z-Score is 4.70, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	22.13B	22.45B	24.69B	27.31B	27.28B	27.12B	28.75B	29.44B
Gross profit	17.27B	17.77B	20.12B	20.70B	21.62B	20.62B	22.50B	23.21B
Selling & admin expenses	4.06B	4.38B	5.15B	5.25B	5.67B	6.06B	6.00B	5.71B
Research & development	3.92B	4.06B	5.04B	4.60B	4.98B	5.72B	5.91B	5.80B
Operating profit	9.30B	9.34B	9.93B	10.86B	10.97B	8.84B	10.60B	11.70B
Pretax profit	7.80B	5.16B	1.67B	8.28B	5.81B	6.86B	690.00M	9.80B
Tax	2.34B	-204.00M	1.58B	2.08B	1.25B	1.25B	211.00M	1.29B
Net profit	5.46B	5.36B	89.00M	6.20B	4.57B	5.61B	480.00M	8.51B
Basic EPS	4	4	0	5	4	5	0	7
Diluted EPS	4.17	4.22	0.10	4.93	3.64	4.50	0.38	6.78

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	6.67B	7.08B	7.77B	7.93B	6.96B	7.80B
Gross profit	5.13B	5.58B	6.20B	6.30B	5.52B	6.22B
Selling & admin expenses	1.26B	1.37B	1.36B	1.73B	1.45B	1.92B
Research & development	1.38B	1.49B	1.35B	1.58B	1.37B	1.76B
Operating profit	2.49B	2.72B	3.50B	2.99B	2.69B	2.54B
Pretax profit	1.65B	2.43B	3.64B	2.08B	2.58B	-10.25B
Tax	334.00M	468.00M	589.00M	-105.00M	559.00M	242.00M
Net profit	1.32B	1.96B	3.05B	2.18B	2.02B	-10.50B
Basic EPS	1	2	2	2	2	-8
Diluted EPS	1.04	1.56	2.43	1.74	1.61	-8.45

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	35.84B	30.30B	16.00B	14.77B	14.44B	16.09B	19.17B	18.34B
Cash & ST investments	30.09B	24.35B	7.41B	6.52B	6.39B	7.26B	11.57B	9.61B
Inventory	814.00M	922.00M	1.68B	1.62B	1.51B	1.79B	1.71B	1.77B
Total assets	63.68B	61.63B	68.41B	67.95B	63.17B	62.13B	59.00B	59.02B
Total current liabilities	10.61B	9.76B	11.40B	11.61B	11.24B	11.28B	12.00B	11.81B
Short-term debt	2.75B	2.50B	2.76B	1.52B	2.27B	1.80B	1.82B	2.81B
Long-term debt	24.57B	22.09B	28.65B	25.18B	22.96B	23.19B	24.90B	22.13B
Total liabilities	42,141,000,000.00	38,977,000,000.00	50,186,000,000.00	46,888,000,000.00	41,962,000,000.00	39,376,000,000.00	39,749,000,000.00	36,405,000,000.00
Total equity	21.53B	22.65B	18.22B	21.06B	21.21B	22.75B	19.25B	22.62B
Retained earnings	19.02B	19.39B	14.38B	16.32B	15.69B	16.30B	11.50B	13.73B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	16.90B	14.72B	17.87B	18.34B	18.64B	13.95B
Cash & ST investments	7.93B	5.21B	7.35B	9.61B	7.64B	3.18B
Inventory	1.76B	1.83B	1.79B	1.77B	1.91B	1.95B
Total assets	56.43B	55.72B	58.53B	59.02B	56.28B	49.36B
Total current liabilities	12.34B	11.19B	12.30B	11.81B	9.48B	11.02B
Short-term debt	2.81B	2.81B	2.81B	2.81B	1.31B	2.41B
Long-term debt	22.15B	22.14B	22.14B	22.13B	20.86B	23.83B
Total liabilities	37,356,000,000.00	36,130,000,000.00	37,077,000,000.00	36,405,000,000.00	32,847,000,000.00	37,618,000,000.00
Total equity	19.08B	19.59B	21.46B	22.62B	23.43B	11.74B
Retained earnings	10.93B	11.33B	12.83B	13.73B	14.13B	2.20B

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	8.40B	9.14B	8.17B	11.38B	9.07B	8.01B	10.83B	10.02B
Depreciation & amortization	1.43B	1.40B	1.48B	2.05B	2.10B	2.69B	2.77B	2.76B
Free cash flow	7.48B	8.32B	7.52B	10.81B	8.34B	7.42B	10.31B	9.46B
Dividends paid	-2.97B	-3.22B	-3.45B	-3.61B	-3.71B	-3.81B	-3.92B	-4.00B
Stock buybacks / issuance	-2.61B	-1.54B	-1.33B	-377.00M	-1.09B	-768.00M	-728.00M	-1.51B
Ending cash balance	17.94B	11.63B	6.00B	5.34B	5.41B	6.09B	9.99B	7.56B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	1.76B	827.00M	4.11B	3.33B	2.54B	3.57B
Depreciation & amortization	696.00M	691.00M	686.00M	687.00M	689.00M	698.00M
Free cash flow	1.65B	720.00M	3.96B	3.12B	2.43B	3.43B
Dividends paid	-1.01B	-994.00M	-1.01B	-994.00M	-1.04B	-1.03B
Stock buybacks / issuance	-478.00M	-500.00M	-338.00M	-198.00M	-253.00M	-346.00M
Ending cash balance	7.93B	5.14B	7.33B	7.56B	7.63B	3.18B

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	26.08	24.53	0.60	31.70	21.71	25.71	2.28	40.49
ROA %	8.14	8.60	0.19	9.13	7.00	9.04	0.79	14.42
ROIC %	12.09	12.76	1.74	14.33	11.30	13.65	2.05	19.42
5-year avg ROE %	63.75	50.59	29.38	21.29	20.93	20.85	16.40	24.38
EBIT margin %	40.11	27.42	10.75	33.98	24.74	28.78	5.80	36.75
FCF / sales %	33.79	37.06	30.45	39.57	30.59	27.37	35.84	32.12
Current ratio	3.38	3.10	1.40	1.27	1.29	1.43	1.60	1.55
Quick ratio	3.15	2.86	1.08	0.95	0.99	1.06	1.33	1.23
Debt / assets	127.75	109.18	172.52	126.70	118.79	109.43	138.18	109.84
LT debt / equity	114.90	98.09	157.37	119.51	108.08	101.56	128.79	97.48
Interest coverage	8.24	6.19	2.70	9.27	7.22	8.27	1.71	10.57
Revenue CAGR (3Y) %	-12.15	-9.60	-1.84	7.26	6.71	3.17	1.74	2.57
Net income CAGR (3Y) %	-32.96	-26.38	-70.16	4.50	-5.18	258.45	-57.44	22.83
FCF CAGR (3Y) %	-28.56	-20.08	-12.72	13.06	0.10	-0.43	-1.57	4.26

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	32.51	33.25	40.54	40.49	43.19	-20.57
ROA %	10.58	11.55	14.35	14.42	16.35	-6.17
ROIC %	15.18	16.05	19.65	19.42	21.78	-6.86
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	27.17	28.41	37.48	36.75	39.45	-3.14
FCF / sales %	34.26	32.46	31.50	32.12	34.40	42.50
Current ratio	1.37	1.32	1.45	1.55	1.97	1.27
Quick ratio	1.00	0.89	1.01	1.23	1.31	0.75
Debt / assets	130.22	126.79	115.79	109.84	94.30	221.90
LT debt / equity	115.57	112.53	102.76	97.48	88.71	201.49
Interest coverage	7.94	8.21	10.71	10.57	11.68	-0.96
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

Revenue breakdown most recent period

Business

Biktarvy48.34%

Descovy12.39%

Other11.65%

Trodelvy5.86%

Yescarta4.43%

Sofosbuvir/Velpatasvir3.88%

Vemlidy3.70%

Genvoya3.70%

Odefsey3.06%

Yeztugo2.97%